Research Progress of Osimertinib Supported by Nanodrug Delivery System Against Non-small Cell Lung Cancer
Osimertinib is an irreversible third representative epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for the treatment of non-small cell lung cancer(NSCLC)with T790M resistance and classical EGFR mutations.However,the therapeutic effectiveness of osimertinib is limited by acquired drug-resistance,poor water solubility and low tumor accumulation rates.Nanodrug delivery systems can increase the solubility and stability of drugs,prolong the blood circulation time of drugs,improve the uptake rate of cells,promote drug accumulation in tumor tissues,and improve drug resistance.Thus,they are effective in overcoming the limitations of traditional targeted drugs.In this study,we reviewed the mechanism of action of the third-generation EGFR-TKI osimertinib,focused on research advances in osimertinib nanodrug delivery systems against NSCLC,and explored the challenges and future development direction in this field.
万方数据
维普
